Publications
55
Citations
1,002
Est. group size
—
Recurring co-author estimate
Active years
36
Publishing since 1990
Meloney Cregor studies bone biology and how diseases and drugs affect skeletal health, using mouse models. Their work examines how conditions such as diabetes, steroid (glucocorticoid) treatment, and the blood cancer multiple myeloma weaken bones, and tests therapies aimed at rebuilding bone mass and strength. They also investigate signals sent between bone cells and other tissues such as the pancreas and fat.
Publication activity has been modest but steady across most years, with a large spike in 2023 and fewer entries afterward.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~11 · 0% small-team papers (≤3 authors) · across 9 venues
- Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice
Bone · 2024
- Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease
JCI Insight · 2024
- Reversal of the diabetic bone signature with anabolic therapies in mice
Bone Research · 2023
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
Bone Research · 2023
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
Bone Research · 2023
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Journal of the Endocrine Society · 2023
- OR29-04 Vitamin D Signaling Prevents Glucocorticoid-Induced Musculoskeletal Tissue Loss And Cardiac Dysfunction By Targeting The Atrogene Pathway
Journal of the Endocrine Society · 2023
- Supplementary figure legends from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Supplementary methods from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Data from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Data from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Supplementary figure legends from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Supplementary methods from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Supplementary figure 2 from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Supplementary figure 1 from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Cancer Research×3
- Bone Research×3
- Endocrinology×2
- Journal of Bone and Mineral Research×2
- PMC×2
- Noriyoshi Kurihara
Medicine · Indiana University
- Stewart A. Low
Medicine · Purdue University West Lafayette
- Laurie K. McCauley
Medicine · University of Michigan
- Joy Y. Wu
Medicine · Purdue University West Lafayette
- Laura E. Wright
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile